ACIP Update

Lisa Grohskopf, MD, MPH
Influenza Division, CDC

NAIIS
May 11, 2017

Some Abbreviations

- **IIV**: Inactivated influenza vaccine
- **LAIV**: Live attenuated influenza vaccine
- **RIV**: Recombinant influenza vaccine
- Numeric suffixes (e.g., RIV3, IIV4) indicate trivalent or quadrivalent, respectively
- Prefixes:  
  - **a** for adjuvanted (e.g., aIIV3)  
  - **cc** for cell culture (e.g., cclIV4)
2016-17 ACIP Influenza Statement--Overview

- **Principal changes**
  - LAIV not recommended for 2016-17 due concerns regarding effectiveness against H1N1pdm09 in U.S. in 2013-14 and 2015-16
  - Licensure of Fluad (allIV3)
  - Licensure of Flucelvax Quadrivalent (ccIV4)
  - Changes to egg allergy recommendations
  - Timing language changed to “providers should offer vaccination by the end of October, if possible” (previously “by October”)

- **Two licensures, one indication change since publication**
  - Afluria Quadrivalent (IIV4)
  - Flublok Quadrivalent (RIV4)
  - Expansion of age indication for FluLaval Quadrivalent (IIV4) at 0.5cc dose to ≥6 months

*MMWR 2016;65(No. RR-5):1–54. DOI: http://dx.doi.org/10.15585/mmwr.rr6505a1.*

Change in LAIV Recommendations--Language

“In light of concerns regarding low effectiveness against influenza A(H1N1)pdm09 in the United States during the 2013–14 and 2015–16 seasons, for the 2016–17 season, ACIP makes the interim recommendation that live attenuated influenza vaccine (LAIV4) should not be used.”
New Vaccine Products Available for 2016-17

- **Flucelvax Quadrivalent (ccIIV4)--Seqirus**
  - Standard-dose IIV4; replaced Flucelvax IIV3 in 2016-17
  - Cell culture-based: unlike other IIVs, viruses are propagated in canine kidney cells instead of eggs
  - Indicated for persons aged ≥4 years

- **Fluad (allIV3)--Seqirus**
  - MF59-adjuvanted IIV3
  - Indicated for persons aged ≥65 years

Other Recent Licensures

- **Afluria Quadrivalent (IIV4)--Seqirus**
  - Standard-dose IIV4
  - Indicated for persons aged ≥18 years
  - Available in addition to Afluria trivalent for 2016-17

- **Flublok Quadrivalent (RIV4)—Protein Sciences**
  - Recombinant quadrivalent influenza vaccine (RIV4)
  - Indicated for persons aged ≥18 years
  - Expected to be available in 2017-18
Another Recent Labelling Change

- **FluLaval Quadrivalent (IIV4)—ID Biomedical Corp. of Quebec/GSK**
  - Previously licensed for ≥3 years; now for ≥6 months
  - Dose is same for all ages (0.5mL, 15μg antigen per virus)
    - Previously only licensed vaccine for 6- through 35-months was 0.25mL Fluzone Quadrivalent (7.5μg antigen per virus)
    - Half dose had been recommended due to increased reactions (particularly fever) with full dose of older, whole-virus vaccines
    - Whole-virus vaccines no longer used
    - Split virus vaccine reactogenicity less in this age group
    - FluLaval Quadrivalent 0.5mL safety similar to half-dose IIV4

Changes to Egg Allergy Language

- **Removal of the 30-minute post-vaccination observation period**
  - 15 minutes is recommended for all vaccines to avoid injury due to syncope

- **Egg-allergic persons can receive any age-appropriate IIV or RIV**
  - RIV not licensed for persons under 18 years of age

- **One additional measure remains for persons with a history of severe allergic reaction to egg (i.e., any symptom other than hives)**
  - The selected vaccine should be administered in an inpatient or outpatient medical setting (including but not necessarily limited to hospitals, clinics, health departments, and physician offices). Vaccine administration should be supervised by a health care provider who is able to recognize and manage severe allergic conditions.
2017-18 Influenza Vaccine Composition

- **Trivalent vaccines:**
  - an A/Michigan/45/2015 (H1N1)pdm09-like virus (new)
    - First change in H1N1 component since 2009 pandemic
    - Still an H1N1pdm09-like virus
  - an A/Hong Kong/4801/2014 (H3N2)-like virus; and
  - a B/Brisbane/60/2008-like virus.

- **Quadrivalent vaccines:**
  - The above three viruses, and
  - a B/Phuket/3073/2013-like virus.

June 2017-18 ACIP Meeting Agenda

- **Influenza surveillance, vaccine effectiveness, and vaccine safety updates**

- **Flublok (RIV) in pregnancy**

- **Afluria trivalent**